Related Experiment Video
Updated: Jan 16, 2026
Sexual Transmission of American Trypanosomes from Males and Females to Naive Mates
Published on: January 27, 2019
Economic burden of Chagas disease in Latin American countries: a population-based cost-of-illness analysis from the
Mônica Viegas Andrade1,2, Kenya Valeria Micaela de Souza Noronha1,2, Aline de Souza1
1Center for Development and Regional Planning, Economics Department, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Background:
Chagas disease (ChD) remains a public health concern in Latin America. Despite a decline in overall prevalence, the chronic symptomatic forms still impose a substantial epidemiological and economic burden. This study undertakes a comprehensive, population-based cost analysis of chronic Chagas disease (CCD) from a societal perspective in seven endemic Latin American countries for 2010 and 2023.
Methods:
A Markov model with one-year cycles and six states was employed. Direct medical and indirect costs, converted to 2024 purchasing power parity US dollars, were estimated using prevalence data from the Global Burden of Disease Study 2023. Based on a previous Brazilian Markov model, parameters were adjusted using healthcare coverage and per capita health expenditure ratios for each country, further validated by national experts.
Findings:
In 2010, Brazil (US$252 billion) and Argentina (US$164 billion) had the highest lifetime burdens. As a percentage of annual Gross Domestic Product, Bolivia (0·9%) and Argentina (0·8%) were most affected. CCD accounted for 6% of total health expenditures in both countries. Between 2010 and 2023, most countries experienced a decline in economic burden due to decreased CCD prevalence, despite an increased proportion of patients with cardiac conditions, reflecting population aging and disease progression.
Interpretation:
CCD imposes substantial economic burden across Latin American countries. Epidemiological shift to older populations with severe cardiac forms signals increased healthcare demands. Findings inform policymakers for resource allocation and tailored interventions.
Funding:
Funding was provided by Novartis Pharma AG as part of a research collaboration with the World Heart Federation (project number CLCZ696D2010R).
Related Concept Videos
01:29Bias in Epidemiological Studies
01:26Methods Of Healthcare Delivery System
Managed Care System:
The managed care system is designed to control the cost while maintaining the quality of care. The patient's care from admission to discharge is planned by the primary care provider or the case manager, also known as the gatekeeper. In a managed care system, the number of care providers is...
01:18Factors Affecting Illness
For instance, risk factors are connected to illness,...
01:08Prevalence and Incidence
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...